期刊
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
卷 79, 期 1, 页码 135-+出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2018.02.027
关键词
adalimumab; apremilast; brodalumab; etanercept; infliximab; ixekizumab; network meta-analysis; plaque psoriasis; secukinumab; ustekinumab
类别
资金
- Institute for Clinical and Economic Review. (ICER)
Background: The comparative effectiveness of available targeted immunomodulators for moderate-to-severe psoriasis has not been evaluated. Objective: To evaluate the comparative effectiveness of targeted immunomodulators for adults with moderate-to-severe plaque psoriasis. Methods: Systematic literature review of placebo-controlled and head-to-head randomized trials of 8 targeted immunomodulators that evaluated clinical benefits or harm. The primary outcome was a 75% improvement on the Psoriasis Area and Severity Index. We also conducted a network meta-analysis adjusted for placebo response to perform indirect comparisons between agents. Results: In the network meta-analysis, the targeted immunomodulators ordered by increasing relative risk (demonstrating greater likelihood) of achieving a 75% improvement on the Psoriasis Area and Severity Index relative to placebo were as follows: apremilast (6.2), etanercept (9.6), adalimumab (13.0), ustekinumab (14.0), secukinumab (15.4), infliximab (16.2), brodalumab (17.3), and ixekizumab (17.9). Ixekizumab, brodalumab, and infliximab were all statistically superior to ustekinumab, adalimumab, etanercept, and apremilast; results were similar to those of head-to-head studies where data were available. Limitations: Much of the evidence is short-term (covering 10-16 weeks); limited direct comparisons. Conclusions: The interleukin 17A inhibitors are more effective in achieving clearance than ustekinumab, and they are generally more effective than etanercept, adalimumab, and apremilast.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据